Institute for Myeloma & Bone Cancer Research Foundation | Strategic Alliance Partners

Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.

BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.

Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.

James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.

Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.